Want to see HK:6833 full AI Analyst Report?
Sinco Pharmaceuticals Holdings Ltd. (6833) Ratios
Sinco Pharmaceuticals Holdings Ltd. Ratios
HK:6833's free cash flow for Q2 2026 was $114.06M. For the 2026 fiscal year, HK:6833's free cash flow was decreased by $-5.10M and operating cash flow was $119.16M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.18 | 1.14 | 1.16 | 1.29 | 1.34 |
| Quick Ratio | 0.95 | 0.87 | 1.08 | 1.17 | 1.25 |
| Cash Ratio | 0.33 | 0.23 | 0.36 | 0.42 | 0.45 |
| Solvency Ratio | 0.05 | 0.05 | 0.05 | 0.09 | 0.16 |
| Operating Cash Flow Ratio | 0.15 | -0.17 | 0.29 | 0.09 | 0.42 |
| Short-Term Operating Cash Flow Coverage | 0.93 | -0.68 | 1.47 | 0.42 | 1.47 |
| Net Current Asset Value | $ 201.88M | $ 174.66M | $ 170.66M | $ 196.88M | $ 111.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.18 | 0.13 | 0.14 | 0.28 |
| Debt-to-Equity Ratio | 0.26 | 0.53 | 0.40 | 0.32 | 0.91 |
| Debt-to-Capital Ratio | 0.21 | 0.35 | 0.29 | 0.24 | 0.48 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 |
| Financial Leverage Ratio | 2.66 | 3.02 | 3.01 | 2.36 | 3.29 |
| Debt Service Coverage Ratio | 0.40 | 0.21 | 0.27 | 0.41 | 0.70 |
| Interest Coverage Ratio | 2.18 | 7.57 | 11.03 | 6.51 | 6.11 |
| Debt to Market Cap | 0.57 | 0.88 | 0.56 | 0.38 | 0.13 |
| Interest Debt Per Share | 0.11 | 0.17 | 0.13 | 0.10 | 0.21 |
| Net Debt to EBITDA | -1.91 | 0.32 | -1.48 | -1.25 | 0.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 10.65% | 10.63% | 12.73% | 13.47% | 18.03% |
| EBIT Margin | 3.58% | 4.04% | 4.32% | 4.46% | 9.51% |
| EBITDA Margin | 4.79% | 4.70% | 4.96% | 4.80% | 9.77% |
| Operating Profit Margin | 3.45% | 3.37% | 4.26% | 3.96% | 8.22% |
| Pretax Profit Margin | 2.32% | 3.51% | 3.93% | 4.37% | 8.27% |
| Net Profit Margin | 1.67% | 1.49% | 1.67% | 3.06% | 6.67% |
| Continuous Operations Profit Margin | 1.67% | 1.49% | 1.67% | 3.06% | 6.67% |
| Net Income Per EBT | 72.22% | 42.50% | 42.40% | 69.96% | 80.70% |
| EBT Per EBIT | 67.03% | 104.19% | 92.34% | 110.38% | 100.60% |
| Return on Assets (ROA) | 1.89% | 2.10% | 2.24% | 4.88% | 10.96% |
| Return on Equity (ROE) | 5.02% | 6.34% | 6.74% | 11.50% | 36.03% |
| Return on Capital Employed (ROCE) | 10.35% | 14.20% | 16.42% | 14.19% | 32.81% |
| Return on Invested Capital (ROIC) | 5.92% | 3.98% | 5.08% | 7.79% | 18.96% |
| Return on Tangible Assets | 2.02% | 2.22% | 2.36% | 5.17% | 10.96% |
| Earnings Yield | 10.78% | 10.81% | 9.78% | 14.61% | 5.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.52 | 4.63 | 4.70 | 6.47 | 9.48 |
| Payables Turnover | 2.04 | 2.84 | 2.56 | 4.82 | 3.92 |
| Inventory Turnover | 7.17 | 7.16 | 20.52 | 21.94 | 26.43 |
| Fixed Asset Turnover | 5.80 | 7.60 | 7.17 | 7.19 | 7.90 |
| Asset Turnover | 1.13 | 1.41 | 1.34 | 1.59 | 1.64 |
| Working Capital Turnover Ratio | 10.86 | 14.78 | 11.87 | 9.66 | 15.67 |
| Cash Conversion Cycle | -24.33 | 1.28 | -47.23 | -2.68 | -40.72 |
| Days of Sales Outstanding | 103.63 | 78.82 | 77.67 | 56.44 | 38.52 |
| Days of Inventory Outstanding | 50.89 | 51.01 | 17.79 | 16.63 | 13.81 |
| Days of Payables Outstanding | 178.85 | 128.54 | 142.69 | 75.76 | 93.04 |
| Operating Cycle | 154.51 | 129.83 | 95.46 | 73.08 | 52.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.08 | -0.11 | 0.17 | 0.04 | 0.18 |
| Free Cash Flow Per Share | 0.08 | -0.13 | 0.14 | 0.01 | 0.16 |
| Dividend Paid and CapEx Coverage Ratio | 12.70 | -5.49 | 4.28 | 1.42 | 13.00 |
| Capital Expenditure Coverage Ratio | 17.34 | -6.62 | 5.48 | 1.42 | 13.00 |
| Operating Cash Flow Coverage Ratio | 0.92 | -0.66 | 1.41 | 0.39 | 0.90 |
| Operating Cash Flow to Sales Ratio | 0.08 | -0.08 | 0.14 | 0.03 | 0.15 |
| Free Cash Flow Yield | 49.42% | -68.91% | 66.80% | 4.71% | 10.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 9.35 | 9.25 | 10.22 | 6.84 | 19.79 |
| Price-to-Sales (P/S) Ratio | 0.16 | 0.14 | 0.17 | 0.21 | 1.32 |
| Price-to-Book (P/B) Ratio | 0.47 | 0.59 | 0.69 | 0.79 | 7.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 2.02 | -1.45 | 1.50 | 21.23 | 9.47 |
| Price-to-Operating Cash Flow Ratio | 1.91 | -1.67 | 1.22 | 6.33 | 8.74 |
| Price-to-Earnings Growth (PEG) Ratio | -0.62 | -19.24 | -0.26 | -0.12 | 1.73 |
| Enterprise Value Multiple | 1.32 | 3.25 | 1.96 | 3.11 | 13.60 |
| Enterprise Value | 132.13M | 431.18M | 246.36M | 338.65M | 2.69B |
| EV to EBITDA | 1.32 | 3.25 | 1.96 | 3.11 | 13.60 |
| EV to Sales | 0.06 | 0.15 | 0.10 | 0.15 | 1.33 |
| EV to Free Cash Flow | 0.83 | -1.61 | 0.85 | 15.12 | 9.53 |
| EV to Operating Cash Flow | 0.78 | -1.85 | 0.70 | 4.51 | 8.79 |
| Tangible Book Value Per Share | 0.28 | 0.26 | 0.26 | 0.26 | 0.22 |
| Shareholders’ Equity Per Share | 0.34 | 0.32 | 0.31 | 0.30 | 0.22 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.28 | 0.57 | 0.58 | 0.30 | 0.19 |
| Revenue Per Share | 1.03 | 1.34 | 1.25 | 1.12 | 1.17 |
| Net Income Per Share | 0.02 | 0.02 | 0.02 | 0.03 | 0.08 |
| Tax Burden | 0.72 | 0.43 | 0.42 | 0.70 | 0.81 |
| Interest Burden | 0.65 | 0.87 | 0.91 | 0.98 | 0.87 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| SG&A to Revenue | 0.07 | 0.07 | 0.04 | 0.04 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 4.99 | -2.35 | 3.54 | 1.08 | 2.26 |
Currency in CNY